Advaxis Inc. (NASDAQ:ADXS)’s share price was up 1.9% on Thursday . The company traded as high as $11.83 and last traded at $11.75, with a volume of 213,703 shares traded. The stock had previously closed at $11.53.

A number of equities analysts have weighed in on ADXS shares. Jefferies Group reaffirmed a “buy” rating on shares of Advaxis in a research note on Thursday, August 25th. HC Wainwright reissued a “buy” rating and issued a $23.00 price objective on shares of Advaxis in a research report on Friday, August 5th. Barclays PLC increased their price objective on shares of Advaxis from $15.00 to $20.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 3rd. Finally, FBR & Co reissued an “outperform” rating and issued a $34.00 price objective on shares of Advaxis in a research report on Tuesday, May 17th. Six analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus price target of $25.80.

The company’s 50-day moving average price is $11.49 and its 200-day moving average price is $9.08. The company’s market cap is $395.67 million.

In related news, Director Richard J. Berman sold 18,000 shares of the business’s stock in a transaction on Monday, August 8th. The shares were sold at an average price of $15.21, for a total transaction of $273,780.00. Following the transaction, the director now owns 66,430 shares of the company’s stock, valued at $1,010,400.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director David Sidransky sold 22,808 shares of the business’s stock in a transaction on Tuesday, August 9th. The stock was sold at an average price of $15.01, for a total transaction of $342,348.08. Following the transaction, the director now directly owns 91,759 shares in the company, valued at approximately $1,377,302.59. The disclosure for this sale can be found here.

Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.